P-COMM-B INDUCTION CHEMOTHERAPY IN INTERMEDIATE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA

被引：1

作者：

PHILLIPS, JK ^{[1
]}

SHERLAWJOHNSON, C ^{[1
]}

DAVIES, JM ^{[1
]}

CLOUGH, JV ^{[1
]}

PARRY, H ^{[1
]}

NASH, JR ^{[1
]}

CAWLEY, JC ^{[1
]}

机构：

[1] UNIV LIVERPOOL,DEPT HAEMATOL,LIVERPOOL,MERSEYSIDE,ENGLAND

来源：

LEUKEMIA & LYMPHOMA | 1995年 / 18卷 / 1-2期

关键词：

NON-HODGKINS LYMPHOMA; CHEMOTHERAPY; MITOXANTRONE;

D O I：

10.3109/10428199509064934

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

57 patients with newly diagnosed intermediate or high grade non-Hodgkin's lymphoma with stage II to IV disease were treated with P-COMM-B (prednisolone, cyclophosphamide, vincristine, mitozantrone, methotrexate and bleomycin). 46% patients achieved a complete remission and 26% achieved a partial remission. Projected disease-free survival in complete remission at 5 years is 56% and projected overall survival at 5 years is 37%. Neutropenia and proximal myopathy were the commonest severe toxicities encountered and two deaths were clearly related to treatment (3.5%). P-COMM-B is effective first-line chemotherapy in intermediate and high grade non-Hodgkin's lymphoma, The efficacy and toxicity of P-COMM-B appear to be comparable to those of the best contemporary regimen, CHOP.

引用

页码：137 / 143

页数：7

共 23 条

[1]

Coltman C.A., Dahlberg S., Jones S.E., CHOP is curative in thirty percent of patients with large cell lymphoma: a twelve year South West Oncology Group (SWOG) follow-up, Advances in cancer chemotherapy. Update on treatment for diffuse large cell lymphoma, pp. P71-P82, (1986)

[2]

Jones S.E., Grozea P.N., Miller T.P., Van Slyck E.J., Balcerzak S.P., Costanzi J.J., Morrison F.S., Eyre H.J., Fabian C.J., Dabich L., Dixon D.O., Hartsock R.J., Grogan T.M., Kjeldsberg C., Schnitzer B., Chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group study, Journal of Clinical Oncology, 3, 10, pp. 1318-1324, (1985)

[3]

McKelvey E.M., Gottlieb J.A., Wilson H.E., Hydroxyldaunorubicin (Adriamycin) combination chemotherapy in malignant lymphoma, Cancer, 38, pp. 1484-1493, (1976)

[4]

Armitage J.O., The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma, Annals of Oncology, 2, pp. 37-41, (1991)

[5]

Klimo J.M., Connors P., MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations, Seminars in Hematology, 25, 2, pp. 41-46, (1987)

[6]

Goldie J.H., Coldman A.J., A mathematical model for relating the drug sensitivity of tumours to the spontaneous mutation rate, Cancer Treatment Reports, 63, pp. 1727-1733, (1979)

[7]

Connors J.M., Klimo P., MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations, Seminars in Hematology, 25, pp. 41-46, (1988)

[8]

Gams R.A., Steinberg J., Posner L., Mitoxantrone in malignant lymphoma, Seminars in Oncology, 11, 1, pp. 3-49, (1984)

[9]

National Cancer Institute sponsored study of clasifications of non-Hodgkins lymphoma: summary and description of a working formulation for clinical usage, Cancer, 49, pp. 2112-2135, (1982)

[10]

Zubrod C.G., Scheiderman M., Frei E., Cancer—appraisal of methods for the study of chemotherapy of cancer in man: Hiophosphoramide, Journal of Chronic Diseases, 11, pp. 7-33, (1960)

← 1 2 3 →